Fluticasone furoate/umeclidinium/vilanterol - GlaxoSmithKline/Innoviva/Theravance Biopharma

Drug Profile

Fluticasone furoate/umeclidinium/vilanterol - GlaxoSmithKline/Innoviva/Theravance Biopharma

Alternative Names: Closed Triple; Elebrato Ellipta; FF/UMEC/VI; Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate; Fluticasone furoate/vilanterol/umeclidinium; GSK 2834425; GW 685698/GSK 573719/GW 642444; ICS/LABA/LAMA - GSK; ICS/LAMA/LABA - GSK; TRELEGY ELLIPTA; Trelegy Ellipta; UMEC/VI/FF; Umeclidinium/fluticasone furoate/vilanterol; Umeclidinium/vilanterol/fluticasone furoate; Vilanterol/fluticasone furoate/umeclidinium; Vilanterol/umeclidinium/fluticasone furoate

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Androstadienes; Anti-inflammatories; Antiasthmatics; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethers; Glucocorticoids; Phenols; Quinuclidines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 29 May 2018 Preregistration for Chronic obstructive pulmonary disease in Japan (Inhalation)
  • 24 Apr 2018 The US FDA approves an sNDA for Chronic obstructive pulmonary disease (maintenance treatment of airflow obstruction and reduction of exacerbations) in USA
  • 24 Apr 2018 The US FDA removes the black box warning from the prescribing information of fluticasone furoate/umeclidinium/vilanterol
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top